Literature DB >> 7032827

The effect of oral prazosin on blood pressure and plasma concentrations of renin and angiotensin II in man.

D McAreavey, A M Cumming, V P Sood, B J Leckie, J J Morton, G D Murray, J I Robertson.   

Abstract

1. We studied the effect of oral prazosin on blood pressure, plasma active renin and angiotensin II in 16 recumbent hypertensive patients between 09.00 and 12.00 hours. 2. In untreated patients there were no significant changes in blood pressure, plasma active renin or angiotensin II during the 3 h period. 3. After an initial dose of prazosin (2 mg) there was a significant fall in recumbent blood pressure with progressive increases in plasma active renin and angiotensin II concentrations. 4. After 3--4 weeks' treatment with oral prazosin only, recumbent blood pressure at 09.00 hours, 15 h after the last dose of prazosin, was significantly lower than before treatment, but plasma active renin and angiotensin II were not significantly different from untreated values. 5. After the usual morning dose of prazosin, blood pressure did not change, but there were significant rises in plasma active renin and angiotensin II, less marked than after the first dose of prazosin. 6. Prazosin therefore stimulates the renin--angiotensin system acutely, both after the initial dose and during long-term therapy; however, no effect on renin and angiotensin II is apparent 15 h after the last dose of prazosin.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7032827     DOI: 10.1042/cs061457s

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  7 in total

1.  The influence of alpha 1-adrenergic blockade on the acute antihypertensive effect of nifedipine.

Authors:  H E Sluiter; F T Huysmans; T A Thien; R A Koene
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

2.  Acute effect of an alpha 1-adrenoceptor antagonist on urinary sodium excretion, plasma atrial natriuretic peptide, arginine vasopressin, and the renin-aldosterone system in healthy subjects.

Authors:  T Tomiyama; T Baba; S Murabayashi; T Ishizaki
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans.

Authors:  J Vincent; W Dachman; T F Blaschke; B B Hoffman
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

4.  Prazosin reduces alcohol drinking throughout prolonged treatment and blocks the initiation of drinking in rats selectively bred for high alcohol intake.

Authors:  Janice C Froehlich; Brett J Hausauer; David L Federoff; Stephen M Fischer; Dennis D Rasmussen
Journal:  Alcohol Clin Exp Res       Date:  2013-06-03       Impact factor: 3.455

Review 5.  Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.

Authors:  R A Young; R N Brogden
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

Review 6.  Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.

Authors:  W F Stanaszek; D Kellerman; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

7.  The Specific α1-Adrenergic Receptor Antagonist Prazosin Influences the Urine Proteome.

Authors:  Mindi Zhao; Jianqiang Wu; Youhe Gao
Journal:  PLoS One       Date:  2016-10-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.